1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin . 2021;71:209-249. doi: 10.3322/caac.21660
2. Cancer stat facts: cervical cancer. National Cancer Institute Surveillance, Epidemiology, and End Results [SEER] Program. Accessed November 14, 2021. https://seer.cancer.gov/statfacts/html/cervix.html
3. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012;131:2349-2359. doi: 10.1002/ijc.27485
4. Winer RL, Hughes JP, Feng Q, et al. Early history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev. 2011;20:699-707. doi: 10.1158/1055-9965.EPI-10-1108
5. Chesson HW, Dunne EF, Hariri F, et al. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41:660-664. doi: 10.1097/OLQ.0000000000000193
6. Human papillomavirus (HPV) and cervical cancer. Fact sheet. Geneva, Switzerland: World Health Organization; November 11, 2020. Accessed November 14, 2021. www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
7. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer . 2007;120:885-891. doi: 10.1002/ijc.22357
8. McCredie MRE, Sharples KJ, Paul C, et al. Natural history of cervical cancer neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008:9:425-434. doi: 10.1016/S1470-2045(08)70103-7
9. de Sanjose S, Quint WG, Alemany I, et al; Retrospective International Survey and HPV Time Trends Study Group . Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective, cross-sectional worldwide study. Lancet Oncol . 2010;11:1048-1056. doi: 10.1016/S1470-2045(10)70230-8
10. Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review 1975-2004 . Bethesda, MD: National Cancer Institute; 2007. Accessed November 14, 2021. https://seer.cancer.gov/archive/csr/1975_2004/#citation
11. Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5:CD009069. doi: 10.1002/14651858.CD009069.pub3
12. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination—updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2016:65;1405-1408. doi: 10.15585/mmwr.mm6549a5
13. Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68:698-702. doi: 10.15585/mmwr.mm6832a3
14. State-level data: Female adolescents receiving 2 or 3 doses of HPV vaccine by age 13-15 years (percent). HealthyPeople.gov. Accessed November 14, 2021. www.healthypeople.gov/2020/data/map/4657?year=2018
15. United States Preventive Services Task Force; Curry SJ, Krist AH, Owens DK, et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA 2018;320:674-686. doi: 10.1001/jama.2018.10897
16. Perkins RB, Guido RS, Castle PE, et al; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24:102-131. doi: 10.1097/LGT.0000000000000525
17. Nayar R, Wilbur DC. The Pap test and Bethesda 2014. Cancer Cytopathol. 2015;123;271-281. doi: 10.1002/cncy.21521
18. Schnatz PF, Guile M, O’Sullivan DM, et al. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol 2006;107:701-708. doi: 10.1097/01.AOG.0000202401.29145.68
19. Zhao C, Florea A, Onisko A, et al. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods. Gynecol Oncol 2009;114:383-389. doi: 10.1016/j.ygyno.2009.05.019
20. Zazove P, Reed BD, Gregoire L, et al. Low false-negative rate of PCR analysis for detecting human papillomavirus-related cervical lesions. J Clin Microbiol. 1998;36:2708-2713. doi: 10.1128/JCM.36.9.2708-2713.1998
21. Richardson LA, El-Zein M, Ramankumar AV, et al; PEACHS (Pap Efficacy After Cervical HPV Status) Study Consortium . HPV DNA testing with cytology triage in cervical cancer screening: influence of revealing HPV infection status. Cancer Cytopathol . 2015:123:745-754. doi: 10.1002/cncy.21596
22. Wentzensen N, Schiffman M, Palmer T, et al. Triage of HPV positive women in cervical cancer screening. J Clin Virol 2016;76:S49-S55. doi: 10.1016/j.jcv.2015.11.015
23. WHO Guidelines: Use of Cryotherapy for Cervical Intraepithelial Neoplasia . Geneva, Switzerland: World Health Organization; 2011. Accessed November 14, 2021. www.ncbi.nlm.nih.gov/books/NBK138476/pdf/Bookshelf_NBK138476.pdf
24. Spence AR, Goggin P, Franco EL. Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev Med. 2007:45:93-106. doi: 10.1016/j.ypmed.2007.06.007
25. Rositch AF, Nowak RG, Gravitt PE. Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000-2009. Cancer. 2014:120:2032-2038. doi: 10.1002/cncr.28548
26. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA: Cancer J Clin. 2021;71:7-33. doi: 10.3322/caac.21654
27. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: cervical cancer. Accessed June 15, 2021. www.nccn.org/professionals/physician_gls/pdf/cervical.pdf
28. Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet . 2017;390:1654-1663. doi: 10.1016/S0140-6736(17)31607-0
29. Osann K, Hsieh S, Nelson EL, et al. Factors associated with poor quality of life among cervical cancer survivors: implications for clinical care and clinical trials. Gynecol Oncol . 2014;135:266 -272. doi: 10.1016/j.ygyno.2014.08.036
30. Ries LAG, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975 to 2003 . Bethesda, MD: National Cancer Institute; 2007. Accessed November 14, 2021. https://seer.cancer.gov/archive/csr/1975_2003/#citation
31. Hu Z, Ding M. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med. 2018;7:5217-5236. doi: 10.1002/cam4.1501
32. Wang R, Pan W, Jin L, et al. Human papillomavirus vaccine against cervical cancer: opportunity and challenge. Cancer Lett . 2020;471:88-102. doi: 10.1016/j.canlet.2019.11.039
